ClinicalTrials.gg
TerminatedNCT07178093Updated Oct 6, 2026

Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization

An interventional study of Antrodia cinnamomea and placebo in Hepatocellular Carcinoma and Transarterial Chemoembolization, sponsored by Taichung Tzu Chi Hospital. Terminated at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Taichung Tzu Chi Hospital · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
poor accrual and insufficient drug supply

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2023, registered Apr 2023).
Updated Oct 6, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 273 studies in Carcinoma, Hepatocellular with a site in Taiwan — 46 open to participants now, 69 under way, 11 of them phase 3. Carcinoma, Hepatocellular · Taiwan.

Enrollment
185th of 224
23 · median 98
Started
2023
with 13 others
No phase
26 of 273
6 open now
Registered
232nd of 273
by date

Among the 273 studies in Carcinoma, Hepatocellular with a site in Taiwan, this one is the 185th largest by enrollment of the 224 interventional ones that give a count, is one of 14 that started in 2023, is one of 26 with no phase, and was the 232nd registered.

Carcinoma, Hepatocellular

3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

46 of the 273 studies in Carcinoma, Hepatocellular with a site in Taiwan are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 273 studies in Carcinoma, Hepatocellular with a site in Taiwan, or all of them as a file.
02

Study summary

Effects of Antrodia cinnamomea on the hepatoma patients after Transcatheter hepatic artery chemoembolization

Read the detailed description

Hepatocellular carcinoma (HCC) accounts for 7% of all cancers worldwide and is the most common, primary liver malignancy globally. It is the second leading cause of cancer-related mortality in Taiwan. Most of the patients with HCCs are associated with hepatitis virus B or C infection, and combined with abnormal liver function or liver cirrhosis. The treatment of HCC includes curative treatment, including surgical resection, liver transplantation, and radiofrequency ablation. Non-curative treatment includes Transcatheter hepatic artery chemoembolization or medical therapy, such as target therapies or immunotherapies. Some patients suffered from post-TACE syndrome, e.g., abdominal pain, nausea, fever, or impaired liver function, after TACE. The clinical application was limited by the possibility of liver function deterioration. There is no standard treatment for the post-TACE syndrome currently. Therapies capable of liver protection could enhance the safety and effect of TACE.

Antrodia cinnamomea (AC) is a medicinal fungal species that has been widely used as a healthy food in Taiwan for the treatment of diverse health-related conditions, in recognition of its anticancer, hepatoprotective, anti-inflammatory, antidiabetic and neuroprotective activities. The properties of antitumor and hepatoprotective make A. cinnamomea extract or its major compounds an ideal candidate for enhancing the treatment effect for HCC.

Many cancer patients in Taiwan took Antrodia cinnamomea products during the course of therapies. In this study, we want to elucidate the effect of Antrodia cinnamomea on the hepatoma patients after Transcatheter hepatic artery chemoembolization, such as the improvement of post-TACE syndrome ( liver function impairment, fever, nausea, and abdominal pain), the quality of life, and hospital stay, etc.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Transarterial Chemoembolization

Keywords

  • hepatocellular carcinoma (HCC), viral hepatitis, Antrodia cinnamomea, post-TACE syndrome
  • hepatocellular carcinoma
  • antrodia cinnamomea
  • post-TACE syndrome
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the form
  • Aged between 20 and 80
  • score class A, B
  • Serum level ≤ 1.5 times the , (ALT) and aspartate aminotransferase (AST) levels ≤ 2 times the upper limit of normal

Exclusion criteria

Exclusion Criteria:

  • Unwillingness to sign the form
  • score class C
  • Patients with main portal vein thrombosis
  • Patients with diffuse liver tumors
  • Those who are allergic to the contrast medium
  • Those with abnormal coagulation function
  • Those with severe dysfunction of brain, heart and lung
  • Patients with severe renal dysfunction (except those receiving renal dialysis)
  • Unable to cooperate
  • Those with uncontrolled arrhythmia and unstable blood pressure
  • Some patients with abnormal thyroid function
  • Any other such as active gastrointestinal bleeding, ascites, or severe portal hypertension
  • Pregnant or lactating women
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Antrodia cinnamomea group

    This group will use Antrodia cinnamomea on the hepatoma patients after Transcatheter hepatic artery chemoembolization. The choice of chemical drug dosage for the patient's hepatic artery embolization is evaluated according to the size of the tumor, which can be divided into 1. Epirubicin 10mg + Lipiodol 10ml 2. Epirubicin 20mg + Lipiodol 10ml; oral dosage form of Antrodia cinnamomea is single capsule/500mg, each oral dose is 2 capsules/1000mg. The experiment lasted for 11 days, and patients were required to take Kangjian Antrodia cinnamomea 3 days before embolization, the day of embolization to the 7th day after surgery, once a day in the morning and evening after meals, 2 capsules each time.

    Dietary Supplement: Antrodia cinnamomea

  • Placebo comparator
    Placebo group

    This group will use placebo on the hepatoma patients after Transcatheter hepatic artery chemoembolization. The choice of chemical drug dosage for the patient's hepatic artery embolization is evaluated according to the size of the tumor, which can be divided into 1. Epirubicin 10mg + Lipiodol 10ml 2. Epirubicin 20mg + Lipiodol 10ml; oral dosage of placebo is 2 capsules twice daily. The experiment lasted for 11 days, and patients were required to take placebo 3 days before embolization, the day of embolization to the 7th day after surgery, once a day in the morning and evening after meals, 2 capsules each time.

    Dietary Supplement: placebo

Interventions

  • Dietary supplementAntrodia cinnamomea

    The experiment lasted for 11 days, and patients were required to take Kangjian Antrodia cinnamomea 3 days before embolization, the day of embolization to the 7th day after surgery, once a day in the morning and evening after meals, 2 capsules each time.

    Also known as: Antrodia cinnamomea group

  • Dietary supplementplacebo

    The experiment lasted for 11 days, and patients were required to take placebo 3 days before embolization, the day of embolization to the 7th day after surgery, once a day in the morning and evening after meals, 2 capsules each time.

06

What researchers measure

Primary outcomes

  1. Changes of serum Aspartate Transaminase (AST) level after TACE

    The serum Aspartate Transaminase (AST) levels after TACE day 1, day 3, day 7, day 28 are compared to the baseline.

    Time frame: 28 days

  2. Changes of serum Alanine Aminotransferase (ALT) level after TACE

    The serum Alanine Aminotransferase (ALT) levels after TACE day 1, day 3, day 7, day 28 are compared to the baseline.

    Time frame: 28 days

  3. Changes of serum total bilirubin level after TACE

    The serum total bilirubin levels after TACE day 1, day 3, day 7, and day 28 are compared to the baseline

    Time frame: 28 days

  4. Changes of serum albumin level after TACE

    The serum albumin levels after TACE day 1, day 3, day 7, and day 28 are compared to the baseline

    Time frame: 28 days

  5. Changes of prothrombin time after TACE

    The prothrombin time after TACE day 1, day 3, day 7, and day 28 are compared to the baseline.

    Time frame: 28 days

Secondary outcomes

  1. Improvement of the quality of life

    European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30 questionnaire) has 30 items, covering both general health status and cancer-related symptoms. Each item is scored on a 4-point Likert scale (1 = "Not at all" to 4 = "Very much"), except for the global health/QoL items, which use a 7-point scale (1 = "Very poor" to 7 = "Excellent"). The differences of the scores after TACE are recorded.

    Time frame: 28 days

07

Study locations

1 site
  • Taichung Tzu-Chi Hospital
    Taichung, Taiwan 406, Taiwan
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2023 to primary completion in Oct 2026, 45 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Dec 2025 → Oct 2026 and completion Dec 2025 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
Sep 17, 2025
StartActual
Jan 1, 2023
Primary completionActual
Oct 2, 2026was Dec 2025
CompletionActual
Oct 2, 2026was Dec 2025
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated poor accrual and insufficient drug supply
changed Oct 6, 2026
Primary completion
Dec 31, 2025→Oct 2, 2026 (actual)
Oct 6, 2026
Study completion
Dec 31, 2025→Oct 2, 2026 (actual)
Oct 6, 2026
Enrollment
60 (estimated)→23 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Terminated
    Why stopped poor accrual and insufficient drug supply
    Primary completion Dec 31, 2025→Oct 2, 2026 (now actual)
    Study completion Dec 31, 2025→Oct 2, 2026 (now actual)
    Enrollment 60 (estimated)→23 (actual)
    + 5 other changes: verification date, oversight details, contact details, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07178093
Lead sponsor
Taichung Tzu Chi Hospital
Responsible party
Yu, Cheng-Chan (Principal Investigator, Taichung Tzu Chi Hospital) — Principal investigator
First posted
Sep 17, 2025
Start date
Jan 1, 2023
Primary completion
Oct 2, 2026
Completion
Oct 2, 2026
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion